세로토닌 5-HT6 저해 활성을 갖는 5-설포닐아미노-5,6-다이하이드로-1H-피라졸로[3,4-c]피리딘-7(4H)-온 화합물
    52.
    发明公开
    세로토닌 5-HT6 저해 활성을 갖는 5-설포닐아미노-5,6-다이하이드로-1H-피라졸로[3,4-c]피리딘-7(4H)-온 화합물 有权
    新型5-磺酰氨基-5,6-二氢-1H-吡唑并[3,4-C]吡啶-7(4H) - 酮化合物,其具有丝氨酸5-HT6的抑制活性

    公开(公告)号:KR1020140118141A

    公开(公告)日:2014-10-08

    申请号:KR1020130033552

    申请日:2013-03-28

    Abstract: The present invention relates to a novel 5-sulfonylamino-5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one compound having an inhibitory activity for 5-HT6, which is one of serotonin subtypes, and a pharmaceutical composition comprising the compound as an active ingredient. Since the novel compound of the present invention has 5-HT6 inhibitory activities, the compound can be used for diagnosing, preventing, and treating central nervous system (CNS) diseases such as Alzheimer′s disease (AD), attention deficit disorder (ADHD), epilepsy, depression, obesity, schizophrenia, sleep disorders, and pain disorders.

    Abstract translation: 本发明涉及对5-HT6具有抑制活性的新的5-磺酰基氨基-5,6-二氢-1H-吡唑并[3,4-c]吡啶-7(4H) - 酮化合物,其为5-羟色胺 亚型和包含该化合物作为活性成分的药物组合物。 由于本发明的新化合物具有5-HT 6抑制活性,所以该化合物可用于诊断,预防和治疗中枢神经系统(CNS)疾病如阿尔茨海默病(AD),注意缺陷障碍(ADHD) ,癫痫,抑郁症,肥胖,精神分裂症,睡眠障碍和疼痛障碍。

    항암활성을 지닌 카르보아졸계 화합물
    55.
    发明公开
    항암활성을 지닌 카르보아졸계 화합물 有权
    具有抗癌活性的新型咔唑类化合物

    公开(公告)号:KR1020120056684A

    公开(公告)日:2012-06-04

    申请号:KR1020100118341

    申请日:2010-11-25

    Abstract: PURPOSE: A carboazole-based compounds with an anticancer activity and a method for preparing the same are provided to prevent and treat cancer. CONSTITUTION: A carboazole-based compound with an anticancer activity is denoted by chemical formula 1. A pharmaceutical composition for anticancer contains the carboazole-based compounds of chemical formula 1. A method for preparing the carboazole-based compounds comprises: a step of reacting amidation of heterocyclic compounds of chemical formula III with 4-haloazole compounds of chemical formula IV to prepare a 4-halocaboazole-based compound of chemical formula V; and a step of performing Suzuki coupling of the compound of chemical formula V with a boronic acid compound of chemical formula VI.

    Abstract translation: 目的:提供具有抗癌活性的基于咔唑的化合物及其制备方法,以预防和治疗癌症。 构成:具有抗癌活性的基于唑的化合物由化学式1表示。用于抗癌的药物组合物含有化学式1的咔唑类化合物。一种制备该类咔唑类化合物的方法包括:使酰胺化反应 的化学式III的4-卤唑化合物的化学式III的杂环化合物,以制备化学式V的4-卤代咔唑类化合物; 以及化学式V化合物与化学式VI的硼酸化合物的Suzuki偶联的步骤。

    GSK-3 억제활성을 보이는 1H-인다졸 화합물
    56.
    发明公开
    GSK-3 억제활성을 보이는 1H-인다졸 화합물 有权
    具有GSK-3抑制活性的1H-吲唑化合物

    公开(公告)号:KR1020120038033A

    公开(公告)日:2012-04-23

    申请号:KR1020100097910

    申请日:2010-10-07

    Abstract: PURPOSE: A 1H-indazole compound with GSK3 inhibition and pharmaceutically acceptable salt thereof are provided to be used as a therapeutic agent for treating diseases caused by GSK-3 activation. CONSTITUTION: A 1H-indazole compounds is denoted by chemical formula 1. A method for preparing the compound comprises: a step of performing amidation of 3-amino-1H-indazole compounds of chemical formula 2 and a substituted carboxylic acid compound of chemical formula 3 under the presence of pyridine base and 1-ethyl-3-(3'-dimethyl aminopropyl)carbodiimide hydrochloride(EDCI).

    Abstract translation: 目的:提供具有GSK3抑制的1H-吲唑化合物及其药学上可接受的盐作为治疗由GSK-3激活引起的疾病的治疗剂。 构成:1H-吲唑化合物由化学式1表示。一种制备化合物的方法包括:进行化学式2的3-氨基-1H-吲唑化合物和化学式3的取代的羧酸化合物的酰胺化步骤 在吡啶碱和1-乙基-3-(3'-二甲基氨基丙基)碳二亚胺盐酸盐(EDCI)的存在下。

    칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
    58.
    发明公开
    칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법 失效
    新型吡咯烷基胺化合物作为钙通道调节剂及其制备方法

    公开(公告)号:KR1020100042111A

    公开(公告)日:2010-04-23

    申请号:KR1020080101249

    申请日:2008-10-15

    Abstract: PURPOSE: A pyrazolylmethylamine-piperazine derivative which is effective as a calcium ion channel modulator is provided to ensure effective activation as an T-type calcium ion channel antagonist and to use as an agent for preventing and treating brain diseases, heart diseases and pain diseases. CONSTITUTION: A pyrazolylmethylamine-peperazine derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing and treating brain diseases, heart diseases or pain diseases by T-type calcium ion channel antagonism contains the pyrazolylmethylamine-peperazine derivative of chemical formula 1 or its pharmaceutically acceptable salt an active ingredient. The brain disease is epilepsy, depression, Parkison's disease, dementia or somnipathy. The heart disease is hypertension, cardiac arrhythmia, myocardial infarction, or congestive failure. The pain disease is chronic pain, acute pain, or neurogenic pain. The pyrazolylmethylamine-peperazine derivative is prepared by binding pyrazolylmethylamine compound of chemical formula 3 with piperazine acetyl halide compound of chemical formula 2.

    Abstract translation: 目的:提供作为钙离子通道调节剂有效的吡唑基甲胺 - 哌嗪衍生物,以确保作为T型钙离子通道拮抗剂的有效活化,并用作预防和治疗脑疾病,心脏病和疼痛疾病的药剂。 构成:吡唑基甲胺 - 哌嗪衍生物由化学式1表示。用于通过T型钙离子通道拮抗作用预防和治疗脑疾病,心脏病或疼痛疾病的药物组合物含有化学式1的吡唑基甲基 - 哌嗪衍生物或其药学上可接受的盐 可接受的盐为活性成分。 脑疾病是癫痫,抑郁症,帕金森病,痴呆或嗜睡。 心脏病是高血压,心律失常,心肌梗死或充血性衰竭。 疼痛疾病是慢性疼痛,急性疼痛或神经源性疼痛。 通过将化学式3的吡唑基甲基胺化合物与化学式2的哌嗪乙酰卤化合物结合,制备吡唑基甲胺 - 哌嗪衍生物。

    신규한 세팔로스포린계 화합물 및 약제학적으로 허용되는염과 그의 제조 방법
    60.
    发明授权
    신규한 세팔로스포린계 화합물 및 약제학적으로 허용되는염과 그의 제조 방법 失效
    新型CEPHOROSPORIN衍生物,其药学上可接受的盐及其制备方法

    公开(公告)号:KR100693298B1

    公开(公告)日:2007-03-13

    申请号:KR1020030042826

    申请日:2003-06-27

    CPC classification number: C07D501/00 Y02P20/55

    Abstract: 본 발명은 하기 화학식 (I)의 신규한 세팔로스포린계 화합물 및 약제학적으로 허용되는 염과 그의 제조 방법에 관한 것이다. 상기 화합물은 메티실린 내성 스타필로코쿠스 아우레우스(MRSA)를 포함하는 그람양성균에 대해 우수한 항균 작용을 나타내므로, 항생제로써 유용하게 사용될 수 있다.
    [화학식 (I)]

    상기 식에서, X, Y 및 Z는 서로 같거나 다를 수 있으며, 각각 독립적으로 수소, 할로겐, C
    1-6 알킬, C
    1-6 알콕시, C
    1-6 할로게노알킬, C
    1-6 알콕시 알킬 또는 C
    3-6 사이클로알킬을 나타내고;
    R
    1 은 하기 화학식 (A)로 표시되는 3-위치가 치환된 이소옥사졸 화합물이며;
    [화학식 (A)]

    (여기서, Q는 세팔로스포린계 화합물에 유용한 치환기로써, 수소, 할로겐, 히드록시, 메르캅토, 시아노, 카르복시, 카르복시산, 에스테르, 카르바모일옥시, 카르바모일, N,N-디메틸카르바모일, C
    1-4 알킬, C
    1-4 알킬옥시, 할로겐이 치환된 알킬, 아릴 또는 헤테로고리 치환체를 나타낸다.)
    R
    2 는 수소, 카르복시기의 유도체로써 에스테르를 만드는 기, 염을 만드는 원자 또는 카르복시기의 보호기를 나타낸다.
    세팔로스포린, 이소옥사졸, 메티실린 내성 스타필로코쿠스 아우레우스, 항균 활성

Patent Agency Ranking